Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma

Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protei...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 63; no. 1; pp. 159 - 172
Main Authors Park, Yun‐Yong, Sohn, Bo Hwa, Johnson, Randy L., Kang, Myoung‐Hee, Kim, Sang Bae, Shim, Jae‐Jun, Mangala, Lingegowda S., Kim, Ji Hoon, Yoo, Jeong Eun, Rodriguez‐Aguayo, Cristian, Pradeep, Sunila, Hwang, Jun Eul, Jang, Hee‐Jin, Lee, Hyun‐Sung, Rupaimoole, Rajesha, Lopez‐Berestein, Gabriel, Jeong, Woojin, Park, Inn Sun, Park, Young Nyun, Sood, Anil K., Mills, Gordon B., Lee, Ju‐Seog
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.01.2016
Subjects
Online AccessGet full text
ISSN0270-9139
1527-3350
DOI10.1002/hep.28223

Cover

Abstract Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protein 1 (YAP1) and transcriptional coactivator with PDZ‐binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up‐regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ‐mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (Hepatology 2016;63:159–172)
AbstractList Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets.
Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (Hepatology 2016;63:159-172)
UNLABELLEDMetabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma.CONCLUSIONYAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets.
Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protein 1 (YAP1) and transcriptional coactivator with PDZ‐binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1 / TAZ regulates amino acid metabolism by up‐regulating expression of the amino acid transporters solute carrier family 38 member 1 ( SLC38A1 ) and solute carrier family 7 member 5 ( SLC7A5 ). Subsequently, increased uptake of amino acids by the transporters ( SLC38A1 and SLC7A5 ) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ‐mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (H epatology 2016;63:159–172)
Author Rodriguez‐Aguayo, Cristian
Lopez‐Berestein, Gabriel
Johnson, Randy L.
Kim, Ji Hoon
Kang, Myoung‐Hee
Hwang, Jun Eul
Jang, Hee‐Jin
Mangala, Lingegowda S.
Sood, Anil K.
Lee, Ju‐Seog
Kim, Sang Bae
Shim, Jae‐Jun
Park, Yun‐Yong
Jeong, Woojin
Yoo, Jeong Eun
Lee, Hyun‐Sung
Sohn, Bo Hwa
Pradeep, Sunila
Park, Inn Sun
Rupaimoole, Rajesha
Park, Young Nyun
Mills, Gordon B.
Author_xml – sequence: 1
  givenname: Yun‐Yong
  surname: Park
  fullname: Park, Yun‐Yong
  organization: University of Ulsan College of Medicine
– sequence: 2
  givenname: Bo Hwa
  surname: Sohn
  fullname: Sohn, Bo Hwa
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 3
  givenname: Randy L.
  surname: Johnson
  fullname: Johnson, Randy L.
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 4
  givenname: Myoung‐Hee
  surname: Kang
  fullname: Kang, Myoung‐Hee
  organization: University of Ulsan College of Medicine
– sequence: 5
  givenname: Sang Bae
  surname: Kim
  fullname: Kim, Sang Bae
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 6
  givenname: Jae‐Jun
  surname: Shim
  fullname: Shim, Jae‐Jun
  organization: Kyung Hee University
– sequence: 7
  givenname: Lingegowda S.
  surname: Mangala
  fullname: Mangala, Lingegowda S.
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 8
  givenname: Ji Hoon
  surname: Kim
  fullname: Kim, Ji Hoon
  organization: Korea University College of Medicine
– sequence: 9
  givenname: Jeong Eun
  surname: Yoo
  fullname: Yoo, Jeong Eun
  organization: Yonsei University College of Medicine
– sequence: 10
  givenname: Cristian
  surname: Rodriguez‐Aguayo
  fullname: Rodriguez‐Aguayo, Cristian
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 11
  givenname: Sunila
  surname: Pradeep
  fullname: Pradeep, Sunila
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 12
  givenname: Jun Eul
  surname: Hwang
  fullname: Hwang, Jun Eul
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 13
  givenname: Hee‐Jin
  surname: Jang
  fullname: Jang, Hee‐Jin
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 14
  givenname: Hyun‐Sung
  surname: Lee
  fullname: Lee, Hyun‐Sung
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 15
  givenname: Rajesha
  surname: Rupaimoole
  fullname: Rupaimoole, Rajesha
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 16
  givenname: Gabriel
  surname: Lopez‐Berestein
  fullname: Lopez‐Berestein, Gabriel
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 17
  givenname: Woojin
  surname: Jeong
  fullname: Jeong, Woojin
  organization: Ewha Woman's University
– sequence: 18
  givenname: Inn Sun
  surname: Park
  fullname: Park, Inn Sun
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 19
  givenname: Young Nyun
  surname: Park
  fullname: Park, Young Nyun
  organization: Yonsei University College of Medicine
– sequence: 20
  givenname: Anil K.
  surname: Sood
  fullname: Sood, Anil K.
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 21
  givenname: Gordon B.
  surname: Mills
  fullname: Mills, Gordon B.
  organization: The University of Texas MD Anderson Cancer Center
– sequence: 22
  givenname: Ju‐Seog
  surname: Lee
  fullname: Lee, Ju‐Seog
  organization: The University of Texas MD Anderson Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26389641$$D View this record in MEDLINE/PubMed
BookMark eNqNkk1uFDEQhS0URH5gwQWQJTawmMQ_3dPtJQqBIEUiC1jAplXtLs84atuN7ckwO47A2TgCJ8HDDCwiEbGwvPneq6pXdUwOfPBIyFPOTjlj4myJ06lohZAPyBGvRTOTsmYH5IiJhs0Ul-qQHKd0wxhTlWgfkUMxl62aV_yI_PiE6ee375BS0BYyDnSKIaP1lFPwA80RfNLRTtkGDyPVAXS2t5BDpGubl_T69eei760frF9QF7I1dI8gzUukDpyD0YKnGeICMw2GRpjAbXSpooObRvxaqk2Ql2vY0H5DIy5WI-StITjrQzG0-1amEDPGRIu0TF3a0DiOBY5UQyyGwcFj8tDAmPDJ_j8hH99cfDi_nF29f_vu_NXVTNdcydnAtBYSAQajse8rGERVI-hGSs5Ub9pGGJSmVgZaUxnZ9hyGEi6WJ9tByhPyYudbEvuywpQ7Z9O2HfAYVqnjTTOfz6u6Vf-B1rxqFeNb9Pkd9CasYom-UIqX_VVSyXuppmYVbxlnhXq2p1a9w6GbonUQN92f9Rfg5Q7QMaQU0fxFOOu2p9WVkLvfp1XYszusthm2Z1EWY8f7FGs74ubf1t3lxfVO8Que8OXN
CODEN HPTLD9
CitedBy_id crossref_primary_10_1177_2472630317698683
crossref_primary_10_1016_j_tcb_2019_10_005
crossref_primary_10_3389_fonc_2020_00928
crossref_primary_10_3389_fonc_2019_01163
crossref_primary_10_3390_cells8040370
crossref_primary_10_1038_s41467_019_09597_w
crossref_primary_10_1146_annurev_cancerbio_030617_050202
crossref_primary_10_18632_aging_102714
crossref_primary_10_3390_v15020324
crossref_primary_10_1016_j_celrep_2020_108609
crossref_primary_10_1016_j_bbcan_2019_03_001
crossref_primary_10_1186_s13062_024_00475_0
crossref_primary_10_15252_embj_2018100294
crossref_primary_10_1016_j_ccell_2021_06_016
crossref_primary_10_3390_microorganisms9010007
crossref_primary_10_1002_adfm_202412705
crossref_primary_10_1002_mco2_340
crossref_primary_10_3390_biomedicines10102512
crossref_primary_10_1158_0008_5472_CAN_23_2994
crossref_primary_10_3390_genes13091585
crossref_primary_10_1002_hep_32490
crossref_primary_10_1038_s41467_022_34559_0
crossref_primary_10_1186_s13046_018_0806_3
crossref_primary_10_15252_embj_2021109365
crossref_primary_10_3724_abbs_2023035
crossref_primary_10_1007_s00253_024_13122_5
crossref_primary_10_1016_j_semcancer_2017_10_007
crossref_primary_10_1158_1535_7163_MCT_21_0071
crossref_primary_10_1016_j_gendis_2019_11_003
crossref_primary_10_1210_endrev_bnac013
crossref_primary_10_1016_j_pharmthera_2017_12_011
crossref_primary_10_1051_fopen_2019023
crossref_primary_10_15252_embr_201643577
crossref_primary_10_3389_fgene_2021_771810
crossref_primary_10_1038_s41598_024_54658_w
crossref_primary_10_1097_FJC_0000000000000736
crossref_primary_10_3389_fcell_2023_1291686
crossref_primary_10_1016_j_canlet_2019_07_015
crossref_primary_10_1155_2023_4364654
crossref_primary_10_1053_j_gastro_2016_10_047
crossref_primary_10_1038_s41467_018_04179_8
crossref_primary_10_1091_mbc_E18_02_0141
crossref_primary_10_3389_fonc_2022_937957
crossref_primary_10_1016_j_cmet_2018_07_010
crossref_primary_10_1038_nrgastro_2016_59
crossref_primary_10_3389_fendo_2024_1344971
crossref_primary_10_1002_mco2_70128
crossref_primary_10_1126_scisignal_aan4667
crossref_primary_10_1016_j_phrs_2019_03_018
crossref_primary_10_1038_s12276_018_0174_2
crossref_primary_10_1042_BSR20171072
crossref_primary_10_1016_j_bioorg_2024_107212
crossref_primary_10_3390_cancers15010186
crossref_primary_10_1038_labinvest_2017_70
crossref_primary_10_1038_s41419_018_1142_4
crossref_primary_10_1038_s41467_018_07394_5
crossref_primary_10_1016_j_celrep_2024_115128
crossref_primary_10_3389_fimmu_2021_624324
crossref_primary_10_1038_s41419_020_02994_w
crossref_primary_10_3389_fmed_2023_1029021
crossref_primary_10_1016_j_drudis_2021_03_004
crossref_primary_10_3748_wjg_v25_i15_1797
crossref_primary_10_1161_CIRCRESAHA_118_314187
crossref_primary_10_1007_s12094_022_02977_7
crossref_primary_10_3892_ijo_2024_5676
crossref_primary_10_3389_fimmu_2024_1377722
crossref_primary_10_1038_s41575_021_00571_w
crossref_primary_10_3390_cells9102308
crossref_primary_10_1038_s41419_023_05598_2
crossref_primary_10_3390_cells7050037
crossref_primary_10_1016_j_ydbio_2020_12_018
crossref_primary_10_1016_j_apsb_2021_09_019
crossref_primary_10_1002_1878_0261_12999
crossref_primary_10_18632_oncotarget_20622
crossref_primary_10_3389_fcell_2024_1335636
crossref_primary_10_1038_s41580_021_00386_2
crossref_primary_10_1096_fj_202002284RR
crossref_primary_10_3390_cells8060600
crossref_primary_10_1128_MCB_00596_20
crossref_primary_10_1002_hep4_1278
crossref_primary_10_1158_1541_7786_MCR_18_0313
crossref_primary_10_1038_s41556_021_00781_z
crossref_primary_10_1038_s42255_022_00584_y
crossref_primary_10_1016_j_bbcan_2022_188787
crossref_primary_10_1002_mco2_375
crossref_primary_10_1016_j_devcel_2020_06_025
crossref_primary_10_3390_cells9092002
crossref_primary_10_1038_ncb3389
crossref_primary_10_1002_hsr2_70343
crossref_primary_10_3390_cells10061416
crossref_primary_10_1016_j_isci_2024_111447
crossref_primary_10_3390_cancers11111648
crossref_primary_10_3389_fphys_2017_00942
crossref_primary_10_1007_s11154_022_09768_z
crossref_primary_10_1186_s12967_024_05027_8
crossref_primary_10_1016_j_bcp_2022_115074
crossref_primary_10_3390_cancers14092151
crossref_primary_10_3389_fphar_2024_1345522
crossref_primary_10_1016_j_molmet_2024_101952
crossref_primary_10_1038_emm_2017_166
crossref_primary_10_1038_s41467_024_55769_8
crossref_primary_10_1002_mef2_59
crossref_primary_10_1158_1541_7786_MCR_19_0756
crossref_primary_10_18632_oncotarget_22666
crossref_primary_10_3389_fonc_2021_631991
crossref_primary_10_1158_1078_0432_CCR_15_2468
crossref_primary_10_1007_s00018_019_03085_6
crossref_primary_10_1016_j_ajpath_2021_05_017
crossref_primary_10_1038_cr_2015_140
crossref_primary_10_3390_ijms24066006
Cites_doi 10.1073/pnas.0912203107
10.1242/dev.045500
10.1073/pnas.0911427107
10.1146/annurev-cellbio-092910-154237
10.1016/j.ccr.2009.09.026
10.1113/expphysiol.1990.sp003382
10.1016/j.tibs.2010.05.003
10.1016/j.cell.2008.11.044
10.1016/j.cell.2007.07.019
10.1002/emmm.201100187
10.1002/hep.24813
10.1006/taap.1998.8555
10.1111/cas.12587
10.1074/jbc.M305597200
10.1371/journal.pone.0075449
10.1038/onc.2009.358
10.1007/s12032-009-9201-4
10.1053/j.gastro.2008.08.008
10.1016/j.ccr.2014.01.010
10.1007/s11912-012-0227-y
10.1101/gad.192856.112
10.1073/pnas.0911409107
10.1038/nrc2981
10.1002/hep.510300212
10.1111/j.2517-6161.1972.tb00899.x
10.1111/cas.12085
10.1002/cncr.24495
10.1101/gad.1664408
10.1016/j.cub.2007.10.039
10.1046/j.1432-1033.2002.03069.x
10.3322/CA.2007.0010
10.1016/j.cell.2006.05.030
10.1038/nrc3458
10.1002/hep.27388
10.1038/nrd3504
10.1038/ncb2615
10.1101/gad.1536007
10.1042/BJ20101912
10.1074/jbc.273.23.14484
10.1038/nrm2221
10.1038/nrgastro.2014.10
10.1002/jcb.25117
10.1158/1078-0432.CCR-12-2587
10.1016/0304-4157(83)90003-5
10.1016/j.mam.2012.07.015
ContentType Journal Article
Copyright 2015 by the American Association for the Study of Liver Diseases
2015 by the American Association for the Study of Liver Diseases.
2016 by the American Association for the Study of Liver Diseases
Copyright_xml – notice: 2015 by the American Association for the Study of Liver Diseases
– notice: 2015 by the American Association for the Study of Liver Diseases.
– notice: 2016 by the American Association for the Study of Liver Diseases
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
DOI 10.1002/hep.28223
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
AIDS and Cancer Research Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
CrossRef
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1527-3350
EndPage 172
ExternalDocumentID 3900918221
26389641
10_1002_hep_28223
HEP28223
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: The 2011 and 2012 cycles of The University of Texas MD Anderson Cancer Center's Sister Institute Network Fund (to J.‐S.L.)
  funderid: 5U54 CA112970‐08 (to G.B.M.) ; 5P01CA099031‐07 (to G.B.M.) ; P30 CA016672 (to G.B.M.)
– fundername: The National Research Foundation of Korea.
  funderid: Bio R&D Program Grant M10642040002‐07N4204‐00210 (to W.J.) ; 2011‐0018055 (to W.J.) ; NRF‐2013R1A2A2A05005990 (to Y.N.P.) ; NRF‐2014R1A1A2053529 (to Y.‐Y.P)
– fundername: The National Institutes of Health
  funderid: MD Anderson Cancer Center's Support Grant (CA016672)
– fundername: NCI NIH HHS
  grantid: U54 CA112970
– fundername: NCI NIH HHS
  grantid: P30 CA016672
– fundername: NCI NIH HHS
  grantid: 5P01CA099031-07
– fundername: NCI NIH HHS
  grantid: CA016672
– fundername: NIDDK NIH HHS
  grantid: R01 DK102611
– fundername: NCI NIH HHS
  grantid: 5U54 CA112970-08
– fundername: NCI NIH HHS
  grantid: R01 CA150229
– fundername: NCI NIH HHS
  grantid: P01 CA099031
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OC
1ZS
1~5
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AALRI
AANHP
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABMAC
ABOCM
ABPVW
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACLDA
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ACZKN
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AECAP
AEEZP
AEIMD
AENEX
AEQDE
AFBPY
AFFNX
AFGKR
AFNMH
AFUWQ
AFZJQ
AGQPQ
AHMBA
AHQVU
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RIG
RIWAO
RJQFR
ROL
RPZ
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
CITATION
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
AAMMB
ADSXY
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
7X8
ID FETCH-LOGICAL-c5193-d0cc23eaadfcebb4ad245eac733109bf872fe3f59fa8f4f38b1ad527e52738d33
IEDL.DBID DR2
ISSN 0270-9139
IngestDate Thu Sep 04 19:19:16 EDT 2025
Thu Sep 04 15:43:30 EDT 2025
Wed Aug 13 10:42:03 EDT 2025
Wed Aug 13 10:39:24 EDT 2025
Thu Apr 03 07:01:45 EDT 2025
Tue Jul 01 03:33:43 EDT 2025
Thu Apr 24 22:56:25 EDT 2025
Thu Apr 24 03:18:00 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2015 by the American Association for the Study of Liver Diseases.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5193-d0cc23eaadfcebb4ad245eac733109bf872fe3f59fa8f4f38b1ad527e52738d33
Notes Supported in part by the 2011 and 2012 cycles of The University of Texas MD Anderson Cancer Center's Sister Institute Network Fund (to J.‐S.L.); 5U54 CA112970‐08 (to G.B.M.), 5P01CA099031‐07 (to G.B.M.), and P30 CA016672 (to G.B.M.); MD Anderson Cancer Center's Support Grant (CA016672) from the National Institutes of Health; Bio R&D Program Grant 2014R1A2A2A01003983 (to W.J.); and 2011‐0018055 (to W.J.), NRF‐2013R1A2A2A05005990 (to Y.N.P.), and NRF‐2014R1A1A2053529 (to Y.‐Y.P) from the National Research Foundation of Korea.
Potential conflict of interest: Nothing to report.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.28223
PMID 26389641
PQID 1750418010
PQPubID 996352
PageCount 14
ParticipantIDs proquest_miscellaneous_1776664589
proquest_miscellaneous_1751489019
proquest_journals_1919424393
proquest_journals_1750418010
pubmed_primary_26389641
crossref_primary_10_1002_hep_28223
crossref_citationtrail_10_1002_hep_28223
wiley_primary_10_1002_hep_28223_HEP28223
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2016
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: January 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Hepatology (Baltimore, Md.)
PublicationTitleAlternate Hepatology
PublicationYear 2016
Publisher Wolters Kluwer Health, Inc
Publisher_xml – name: Wolters Kluwer Health, Inc
References 2011; 138
2007; 17
1990; 75
2009; 87
2011; 436
2010; 35
2010; 107
2013; 104
2008; 58
2011; 11
2014; 25
2011; 10
2012; 18
2014; 2014
2015; 106
2007; 31
2012; 14
2013; 8
2003; 278
2012; 55
1983; 737
2009; 136
2009; 115
1998; 273
2010; 27
2015; 116
2013; 13
2010; 29
2015; 61
2013; 34
2007; 130
2005; 326
2007; 8
1999; 154
2002; 269
2008; 22
1999; 30
2008; 135
2012; 26
2007; 21
2011; 27
2012; 4
1972; 34
2012; 5
2009; 16
2014; 11
2006; 125
(hep28223-bib-0033-20241017) 2002; 269
(hep28223-bib-0015-20241017) 2015; 61
(hep28223-bib-0038-20241017) 2013; 8
(hep28223-bib-0004-20241017) 2007; 8
(hep28223-bib-0028-20241017) 1990; 75
(hep28223-bib-0016-20241017) 2008; 58
(hep28223-bib-0010-20241017) 2009; 16
(hep28223-bib-0042-20241017) 1999; 154
(hep28223-bib-0011-20241017) 2013; 13
(hep28223-bib-0021-20241017) 2011; 11
(hep28223-bib-0041-20241017) 2010; 27
(hep28223-bib-0048-20241017) 2012; 14
(hep28223-bib-0043-20241017) 2012; 5
(hep28223-bib-0005-20241017) 2006; 125
(hep28223-bib-0025-20241017) 2009; 87
(hep28223-bib-0024-20241017) 2011; 436
(hep28223-bib-0046-20241017) 2012; 26
(hep28223-bib-0002-20241017) 2007; 21
(hep28223-bib-0007-20241017) 2010; 107
(hep28223-bib-0032-20241017) 2009; 136
(hep28223-bib-0003-20241017) 2007; 130
(hep28223-bib-0044-20241017) 2007; 31
(hep28223-bib-0018-20241017) 2012; 4
(hep28223-bib-0029-20241017) 1983; 737
(hep28223-bib-0036-20241017) 2015; 106
(hep28223-bib-0035-20241017) 2015; 116
(hep28223-bib-0012-20241017) 2011; 10
(hep28223-bib-0020-20241017) 1972; 34
(hep28223-bib-0039-20241017) 2014; 2014
(hep28223-bib-0030-20241017) 1998; 273
(hep28223-bib-0040-20241017) 2008; 135
(hep28223-bib-0006-20241017) 2007; 17
(hep28223-bib-0019-20241017) 2003; 278
(hep28223-bib-0027-20241017) 2010; 35
(hep28223-bib-0031-20241017) 2005; 326
(hep28223-bib-0014-20241017) 2012; 18
(hep28223-bib-0037-20241017) 2009; 115
(hep28223-bib-0001-20241017) 2011; 138
(hep28223-bib-0008-20241017) 2010; 107
(hep28223-bib-0045-20241017) 2012; 14
(hep28223-bib-0047-20241017) 2014; 25
(hep28223-bib-0049-20241017) 1999; 30
(hep28223-bib-0017-20241017) 2014; 11
(hep28223-bib-0023-20241017) 2008; 22
(hep28223-bib-0026-20241017) 2010; 29
(hep28223-bib-0013-20241017) 2013; 104
(hep28223-bib-0009-20241017) 2010; 107
(hep28223-bib-0050-20241017) 2013; 34
(hep28223-bib-0034-20241017) 2012; 55
(hep28223-bib-0022-20241017) 2011; 27
References_xml – volume: 22
  start-page: 1962
  year: 2008
  end-page: 1971
  article-title: TEAD mediates YAP‐dependent gene induction and growth control
  publication-title: Genes Dev
– volume: 130
  start-page: 1120
  year: 2007
  end-page: 1133
  article-title: Elucidation of a universal size‐control mechanism in and mammals
  publication-title: Cell
– volume: 107
  start-page: 1437
  year: 2010
  end-page: 1442
  article-title: Hippo signaling is a potent growth and tumor suppressor pathway in the mammalian liver
  publication-title: Proc Natl Acad Sci USA
– volume: 58
  start-page: 71
  year: 2008
  end-page: 96
  article-title: Cancer statistics, 2008
  publication-title: CA Cancer J Clin
– volume: 10
  start-page: 671
  year: 2011
  end-page: 684
  article-title: Targeting cancer metabolism: a therapeutic window opens
  publication-title: Nat Rev Drug Discov
– volume: 5
  start-page: 410
  year: 2012
  end-page: 414
  article-title: Differences in Yes‐associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma
  publication-title: Mol Med Report
– volume: 326
  start-page: 174
  year: 2005
  end-page: 180
  article-title: Glutamine is a key regulator for amino acid‐controlled cell growth through the mTOR signaling pathway in rat intestinal epithelial cells
  publication-title: Biochem Biophys Res Commun
– volume: 26
  start-page: 1300
  year: 2012
  end-page: 1305
  article-title: Genetic and pharmacological disruption of the TEAD‐YAP complex suppresses the oncogenic activity of YAP
  publication-title: Genes Dev
– volume: 154
  start-page: 84
  year: 1999
  end-page: 96
  article-title: TA1 oncofetal rat liver cDNA and putative amino acid permease: temporal correlation with c‐myc during acute CCl liver injury and variation of RNA levels in response to amino acids in hepatocyte cultures
  publication-title: Toxicol Appl Pharmacol
– volume: 61
  start-page: 191
  year: 2015
  end-page: 199
  article-title: Emerging trends in hepatocellular carcinoma incidence and mortality
  publication-title: Hepatology
– volume: 136
  start-page: 521
  year: 2009
  end-page: 534
  article-title: Bidirectional transport of amino acids regulates mTOR and autophagy
  publication-title: Cell
– volume: 14
  start-page: 1322
  year: 2012
  end-page: 1329
  article-title: YAP mediates crosstalk between the Hippo and PI(3)K‐TOR pathways by suppressing PTEN via miR‐29
  publication-title: Nat Cell Biol
– volume: 75
  start-page: 3
  year: 1990
  end-page: 26
  article-title: The identification of neutral amino acid transport systems
  publication-title: Exp Physiol
– volume: 135
  start-page: 1972
  year: 2008
  end-page: 1983
  article-title: Pivotal role of mTOR signaling in hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 11
  start-page: 447
  year: 2014
  end-page: 452
  article-title: HCC therapies—lessons learned
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 138
  start-page: 9
  year: 2011
  end-page: 22
  article-title: Hippo signaling: growth control and beyond
  publication-title: Development
– volume: 29
  start-page: 313
  year: 2010
  end-page: 324
  article-title: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
  publication-title: Oncogene
– volume: 17
  start-page: 2054
  year: 2007
  end-page: 2060
  article-title: YAP1 increases organ size and expands undifferentiated progenitor cells
  publication-title: Curr Biol
– volume: 16
  start-page: 425
  year: 2009
  end-page: 438
  article-title: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene
  publication-title: Cancer Cell
– volume: 278
  start-page: 33334
  year: 2003
  end-page: 33341
  article-title: WW domain‐containing protein YAP associates with ErbB‐4 and acts as a co‐transcriptional activator for the carboxyl‐terminal fragment of ErbB‐4 that translocates to the nucleus
  publication-title: J Biol Chem
– volume: 35
  start-page: 427
  year: 2010
  end-page: 433
  article-title: Glutamine addiction: a new therapeutic target in cancer
  publication-title: Trends Biochem Sci
– volume: 55
  start-page: 1443
  year: 2012
  end-page: 1452
  article-title: 65‐gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 14
  start-page: 129
  year: 2012
  end-page: 138
  article-title: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies
  publication-title: Curr Oncol Rep
– volume: 737
  start-page: 267
  year: 1983
  end-page: 284
  article-title: The regulation of neutral amino acid transport in mammalian cells
  publication-title: Biochim Biophys Acta
– volume: 115
  start-page: 4576
  year: 2009
  end-page: 4585
  article-title: Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
  publication-title: Cancer
– volume: 34
  start-page: 702
  year: 2013
  end-page: 710
  article-title: Solute carriers as drug targets: current use, clinical trials and prospective
  publication-title: Mol Aspects Med
– volume: 116
  start-page: 2465
  year: 2015
  end-page: 2475
  article-title: Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma
  publication-title: J Cell Biochem
– volume: 106
  start-page: 151
  year: 2015
  end-page: 159
  article-title: TAZ regulates cell proliferation and epithelial‐mesenchymal transition of human hepatocellular carcinoma
  publication-title: Cancer Sci
– volume: 104
  start-page: 275
  year: 2013
  end-page: 281
  article-title: Cancer metabolism: key players in metabolic reprogramming
  publication-title: Cancer Sci
– volume: 25
  start-page: 166
  year: 2014
  end-page: 180
  article-title: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer
  publication-title: Cancer Cell
– volume: 87
  start-page: 77
  year: 2009
  end-page: 91
  article-title: YAP, TAZ, and Yorkie: a conserved family of signal‐responsive transcriptional coregulators in animal development and human disease
  publication-title: Biochem Cell Biol
– volume: 273
  start-page: 14484
  year: 1998
  end-page: 14494
  article-title: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF‐4E BP1 through a common effector mechanism
  publication-title: J Biol Chem
– volume: 107
  start-page: 8248
  year: 2010
  end-page: 8253
  article-title: The Hippo‐Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
  publication-title: Proc Natl Acad Sci USA
– volume: 4
  start-page: 52
  year: 2012
  end-page: 67
  article-title: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer
  publication-title: EMBO Mol Med
– volume: 34
  start-page: 187
  year: 1972
  end-page: 220
  article-title: Regression models with life tables
  publication-title: J R Stat Soc
– volume: 27
  start-page: 255
  year: 2010
  end-page: 261
  article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
  publication-title: Med Oncol
– volume: 8
  start-page: e75449
  year: 2013
  article-title: Increased expression of Yes‐associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular‐cholangiocarcinoma
  publication-title: PLoS One
– volume: 30
  start-page: 437
  year: 1999
  end-page: 444
  article-title: Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat
  publication-title: Hepatology
– volume: 18
  start-page: 5537
  year: 2012
  end-page: 5545
  article-title: Targeting cancer metabolism
  publication-title: Clin Cancer Res
– volume: 125
  start-page: 1253
  year: 2006
  end-page: 1267
  article-title: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
  publication-title: Cell
– volume: 11
  start-page: 85
  year: 2011
  end-page: 95
  article-title: Regulation of cancer cell metabolism
  publication-title: Nat Rev Cancer
– volume: 27
  start-page: 441
  year: 2011
  end-page: 464
  article-title: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation
  publication-title: Annu Rev Cell Dev Biol
– volume: 107
  start-page: 1431
  year: 2010
  end-page: 1436
  article-title: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression
  publication-title: Proc Natl Acad Sci USA
– volume: 13
  start-page: 246
  year: 2013
  end-page: 257
  article-title: The Hippo pathway and human cancer
  publication-title: Nat Rev Cancer
– volume: 8
  start-page: 613
  year: 2007
  end-page: 621
  article-title: Filling out the Hippo pathway
  publication-title: Nat Rev Mol Cell Biol
– volume: 2014
  start-page: 261365
  year: 2014
  article-title: Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma
  publication-title: J Immunol Res
– volume: 31
  start-page: 81
  year: 2007
  end-page: 87
  article-title: Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues
  publication-title: Int J Oncol
– volume: 436
  start-page: 193
  year: 2011
  end-page: 211
  article-title: The role of amino acid transporters in inherited and acquired diseases
  publication-title: Biochem J
– volume: 21
  start-page: 886
  year: 2007
  end-page: 897
  article-title: Hippo signaling in organ size control
  publication-title: Genes Dev
– volume: 269
  start-page: 3742
  year: 2002
  end-page: 3750
  article-title: Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes
  publication-title: Eur J Biochem
– volume: 107
  start-page: 8248
  year: 2010
  ident: hep28223-bib-0008-20241017
  article-title: The Hippo‐Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0912203107
– volume: 138
  start-page: 9
  year: 2011
  ident: hep28223-bib-0001-20241017
  article-title: Hippo signaling: growth control and beyond
  publication-title: Development
  doi: 10.1242/dev.045500
– volume: 107
  start-page: 1437
  year: 2010
  ident: hep28223-bib-0007-20241017
  article-title: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0911427107
– volume: 27
  start-page: 441
  year: 2011
  ident: hep28223-bib-0022-20241017
  article-title: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation
  publication-title: Annu Rev Cell Dev Biol
  doi: 10.1146/annurev-cellbio-092910-154237
– volume: 16
  start-page: 425
  year: 2009
  ident: hep28223-bib-0010-20241017
  article-title: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.09.026
– volume: 2014
  start-page: 261365
  year: 2014
  ident: hep28223-bib-0039-20241017
  article-title: Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma
  publication-title: J Immunol Res
– volume: 75
  start-page: 3
  year: 1990
  ident: hep28223-bib-0028-20241017
  article-title: The identification of neutral amino acid transport systems
  publication-title: Exp Physiol
  doi: 10.1113/expphysiol.1990.sp003382
– volume: 35
  start-page: 427
  year: 2010
  ident: hep28223-bib-0027-20241017
  article-title: Glutamine addiction: a new therapeutic target in cancer
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2010.05.003
– volume: 136
  start-page: 521
  year: 2009
  ident: hep28223-bib-0032-20241017
  article-title: Bidirectional transport of amino acids regulates mTOR and autophagy
  publication-title: Cell
  doi: 10.1016/j.cell.2008.11.044
– volume: 130
  start-page: 1120
  year: 2007
  ident: hep28223-bib-0003-20241017
  article-title: Elucidation of a universal size‐control mechanism in Drosophila and mammals
  publication-title: Cell
  doi: 10.1016/j.cell.2007.07.019
– volume: 4
  start-page: 52
  year: 2012
  ident: hep28223-bib-0018-20241017
  article-title: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201100187
– volume: 55
  start-page: 1443
  year: 2012
  ident: hep28223-bib-0034-20241017
  article-title: 65‐gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.24813
– volume: 154
  start-page: 84
  year: 1999
  ident: hep28223-bib-0042-20241017
  article-title: TA1 oncofetal rat liver cDNA and putative amino acid permease: temporal correlation with c‐myc during acute CCl4 liver injury and variation of RNA levels in response to amino acids in hepatocyte cultures
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1006/taap.1998.8555
– volume: 106
  start-page: 151
  year: 2015
  ident: hep28223-bib-0036-20241017
  article-title: TAZ regulates cell proliferation and epithelial‐mesenchymal transition of human hepatocellular carcinoma
  publication-title: Cancer Sci
  doi: 10.1111/cas.12587
– volume: 278
  start-page: 33334
  year: 2003
  ident: hep28223-bib-0019-20241017
  article-title: WW domain‐containing protein YAP associates with ErbB‐4 and acts as a co‐transcriptional activator for the carboxyl‐terminal fragment of ErbB‐4 that translocates to the nucleus
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M305597200
– volume: 8
  start-page: e75449
  year: 2013
  ident: hep28223-bib-0038-20241017
  article-title: Increased expression of Yes‐associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular‐cholangiocarcinoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0075449
– volume: 29
  start-page: 313
  year: 2010
  ident: hep28223-bib-0026-20241017
  article-title: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
  publication-title: Oncogene
  doi: 10.1038/onc.2009.358
– volume: 27
  start-page: 255
  year: 2010
  ident: hep28223-bib-0041-20241017
  article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
  publication-title: Med Oncol
  doi: 10.1007/s12032-009-9201-4
– volume: 5
  start-page: 410
  year: 2012
  ident: hep28223-bib-0043-20241017
  article-title: Differences in Yes‐associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma
  publication-title: Mol Med Report
– volume: 135
  start-page: 1972
  year: 2008
  ident: hep28223-bib-0040-20241017
  article-title: Pivotal role of mTOR signaling in hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.08.008
– volume: 25
  start-page: 166
  year: 2014
  ident: hep28223-bib-0047-20241017
  article-title: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.01.010
– volume: 14
  start-page: 129
  year: 2012
  ident: hep28223-bib-0048-20241017
  article-title: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-012-0227-y
– volume: 26
  start-page: 1300
  year: 2012
  ident: hep28223-bib-0046-20241017
  article-title: Genetic and pharmacological disruption of the TEAD‐YAP complex suppresses the oncogenic activity of YAP
  publication-title: Genes Dev
  doi: 10.1101/gad.192856.112
– volume: 107
  start-page: 1431
  year: 2010
  ident: hep28223-bib-0009-20241017
  article-title: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0911409107
– volume: 11
  start-page: 85
  year: 2011
  ident: hep28223-bib-0021-20241017
  article-title: Regulation of cancer cell metabolism
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2981
– volume: 30
  start-page: 437
  year: 1999
  ident: hep28223-bib-0049-20241017
  article-title: Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat
  publication-title: Hepatology
  doi: 10.1002/hep.510300212
– volume: 34
  start-page: 187
  year: 1972
  ident: hep28223-bib-0020-20241017
  article-title: Regression models with life tables
  publication-title: J R Stat Soc
  doi: 10.1111/j.2517-6161.1972.tb00899.x
– volume: 104
  start-page: 275
  year: 2013
  ident: hep28223-bib-0013-20241017
  article-title: Cancer metabolism: key players in metabolic reprogramming
  publication-title: Cancer Sci
  doi: 10.1111/cas.12085
– volume: 326
  start-page: 174
  year: 2005
  ident: hep28223-bib-0031-20241017
  article-title: Glutamine is a key regulator for amino acid‐controlled cell growth through the mTOR signaling pathway in rat intestinal epithelial cells
  publication-title: Biochem Biophys Res Commun
– volume: 115
  start-page: 4576
  year: 2009
  ident: hep28223-bib-0037-20241017
  article-title: Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.24495
– volume: 22
  start-page: 1962
  year: 2008
  ident: hep28223-bib-0023-20241017
  article-title: TEAD mediates YAP‐dependent gene induction and growth control
  publication-title: Genes Dev
  doi: 10.1101/gad.1664408
– volume: 17
  start-page: 2054
  year: 2007
  ident: hep28223-bib-0006-20241017
  article-title: YAP1 increases organ size and expands undifferentiated progenitor cells
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2007.10.039
– volume: 269
  start-page: 3742
  year: 2002
  ident: hep28223-bib-0033-20241017
  article-title: Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes
  publication-title: Eur J Biochem
  doi: 10.1046/j.1432-1033.2002.03069.x
– volume: 58
  start-page: 71
  year: 2008
  ident: hep28223-bib-0016-20241017
  article-title: Cancer statistics, 2008
  publication-title: CA Cancer J Clin
  doi: 10.3322/CA.2007.0010
– volume: 125
  start-page: 1253
  year: 2006
  ident: hep28223-bib-0005-20241017
  article-title: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
  publication-title: Cell
  doi: 10.1016/j.cell.2006.05.030
– volume: 13
  start-page: 246
  year: 2013
  ident: hep28223-bib-0011-20241017
  article-title: The Hippo pathway and human cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3458
– volume: 61
  start-page: 191
  year: 2015
  ident: hep28223-bib-0015-20241017
  article-title: Emerging trends in hepatocellular carcinoma incidence and mortality
  publication-title: Hepatology
  doi: 10.1002/hep.27388
– volume: 10
  start-page: 671
  year: 2011
  ident: hep28223-bib-0012-20241017
  article-title: Targeting cancer metabolism: a therapeutic window opens
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3504
– volume: 87
  start-page: 77
  year: 2009
  ident: hep28223-bib-0025-20241017
  article-title: YAP, TAZ, and Yorkie: a conserved family of signal‐responsive transcriptional coregulators in animal development and human disease
  publication-title: Biochem Cell Biol
– volume: 14
  start-page: 1322
  year: 2012
  ident: hep28223-bib-0045-20241017
  article-title: YAP mediates crosstalk between the Hippo and PI(3)K‐TOR pathways by suppressing PTEN via miR‐29
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb2615
– volume: 21
  start-page: 886
  year: 2007
  ident: hep28223-bib-0002-20241017
  article-title: Hippo signaling in organ size control
  publication-title: Genes Dev
  doi: 10.1101/gad.1536007
– volume: 436
  start-page: 193
  year: 2011
  ident: hep28223-bib-0024-20241017
  article-title: The role of amino acid transporters in inherited and acquired diseases
  publication-title: Biochem J
  doi: 10.1042/BJ20101912
– volume: 273
  start-page: 14484
  year: 1998
  ident: hep28223-bib-0030-20241017
  article-title: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF‐4E BP1 through a common effector mechanism
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.23.14484
– volume: 31
  start-page: 81
  year: 2007
  ident: hep28223-bib-0044-20241017
  article-title: Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues
  publication-title: Int J Oncol
– volume: 8
  start-page: 613
  year: 2007
  ident: hep28223-bib-0004-20241017
  article-title: Filling out the Hippo pathway
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2221
– volume: 11
  start-page: 447
  year: 2014
  ident: hep28223-bib-0017-20241017
  article-title: HCC therapies—lessons learned
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2014.10
– volume: 116
  start-page: 2465
  year: 2015
  ident: hep28223-bib-0035-20241017
  article-title: Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.25117
– volume: 18
  start-page: 5537
  year: 2012
  ident: hep28223-bib-0014-20241017
  article-title: Targeting cancer metabolism
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-2587
– volume: 737
  start-page: 267
  year: 1983
  ident: hep28223-bib-0029-20241017
  article-title: The regulation of neutral amino acid transport in mammalian cells
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0304-4157(83)90003-5
– volume: 34
  start-page: 702
  year: 2013
  ident: hep28223-bib-0050-20241017
  article-title: Solute carriers as drug targets: current use, clinical trials and prospective
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2012.07.015
SSID ssj0009428
Score 2.5226626
Snippet Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including...
UNLABELLEDMetabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 159
SubjectTerms Adaptor Proteins, Signal Transducing - genetics
Adaptor Proteins, Signal Transducing - physiology
Amino Acid Transport Systems - physiology
Amino acids
Animals
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - metabolism
Cell growth
Cell proliferation
Female
Gene Expression Regulation, Neoplastic
Hepatocellular carcinoma
Hepatology
Humans
Intracellular Signaling Peptides and Proteins - physiology
Liver cancer
Liver Neoplasms - genetics
Liver Neoplasms - metabolism
Mechanistic Target of Rapamycin Complex 1
Metabolic activation
Metabolic pathways
Metabolic rate
Metabolism
Mice
Multiprotein Complexes - physiology
Phosphoproteins - genetics
Phosphoproteins - physiology
Protein Structure, Tertiary
Rapamycin
Signal Transduction
TOR protein
TOR Serine-Threonine Kinases - physiology
Trans-Activators
Transcription
Transcription Factors
Tumor suppressor genes
Tumorigenesis
Yes-associated protein
Title Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28223
https://www.ncbi.nlm.nih.gov/pubmed/26389641
https://www.proquest.com/docview/1750418010
https://www.proquest.com/docview/1919424393
https://www.proquest.com/docview/1751489019
https://www.proquest.com/docview/1776664589
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAX3o9CqQziwCXbOLGziTgh2moBFVWISgUhRX6MYQVJqn0Ay4mfwG_jJ_BLmHEeVaEgxG2lzHjHyYz92R5_w9h94YWwjmhDhYJIKpVFJlZJlCKai7WCOHV0orv_PJscyqdH6miNPezvwrT8EMOGG0VGGK8pwLWZb5-Qhr6D4xHlQBLTp0gz4s3feXFCHVXIUFcVV10xnS4XPatQnGwPmqfnot8A5mm8GiacvYvsTW9qm2fyfrRcmJH98guL43_25RK70AFR_qj1nMtsDeor7Nx-d9R-lX1_BfMfX7_p7vOB44HSYVpzwXXt-IImuX7IwYZsQ1ckPtIantPmLj_YeY36ZhquzXDK-fO8EwGOsJNXuqrCLgtv09F54znVY69WaAEPue7wGf-NiiZ_0ituVnwGb0O5MWxQV9O6wQannSmBoH0256iK_UQz6EiCcmy5pXJJdVPpa-xwb_fl40nUFYCILAHLyMXWJilo7bwFY6R2iVQ4U1CdybgwPh8nHlKvCq9zL32aG6GdSsYQWOVcml5n63VTw03GLcrmoMUYByjpwRUxaisDhSlyqyRssAe9K5S2Y0enIh0fypbXOSnR9jJ8ow12bxA9bilBzhLa7P2p7EaFeSmIS18gJojPflwI9FpEiKh9d3iM4U4vTNfQLEMTuIBFEFf8TWaMi1KpcpS50bryYGhCCDWTAvsbHPLPPSgnuwfhx61_F73NziOgzChHL0k32fpitoQ7CNoWZguj88mzrRCjPwFi7EUY
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKkYAX7pdCAYN44CXbOLF3E4kXBK0W6FYVaqWChCJfxrCCJNVegOWJT-Db-AS-hBkn2apQEOJtpcx4x8nYPh6PzzD2QHghrCPaUKEgkkr1IxOrJEoRzcVaQZw6OtEd7fSH-_L5gTpYYY-6uzANP8Qy4EYjI8zXNMApIL1xxBr6Dg57lASZnmKnw_kcQaKXR-RRuQyVVXHfFdP5ct7xCsXJxlL1-Gr0G8Q8jljDkrN1gb3pjG0yTd735jPTs19-4XH8395cZOdbLMofN85zia1AdZmdGbWn7VfY91cw_fH1m26_IDgeWB3GFRdcV47PaJ3rZh1syNZ0S-IjbeM5xXf57tPXqG_G4eYMp7Q_z1sR4Ig8eanLMgRaeJORzmvPqSR7uUALeEh3h8_4b1Q3-ZNecLPgE3gbKo5hg7ocVzU2OG5NCRztkylHVewnmkGnEpRmyy1VTKrqUl9l-1ube0-GUVsDIrKELSMXW5ukoLXzFoyR2iVS4WJBpSbj3PhskHhIvcq9zrz0aWaEdioZQCCWc2l6ja1WdQU3GLcom4EWA5yjpAeXx6itDOQmz6ySsMYedr5Q2JYgnep0fCgaauekQNuL8I3W2P2l6GHDCnKS0HrnUEU7MUwLQXT6AmFBfPLjXKDbIkhE7XvLxzji6YXpCup5aAL3sIjj8r_JDHBfKlWGMtcbX14amhBI7UuB_Q0e-eceFMPN3fDj5r-L3mVnh3uj7WL72c6LW-wc4ss2YrXOVmeTOdxGDDczd8JQ_QnQP0g3
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKkSpeuFMKBQzigZds48TejcUTol0tl1YrRKWCkCJfYQVJVnsBlic-gW_jE_gSZpxLVSgI8bZSZrzjZOw5tsdnCLnPPGPGIm0oEy7iQvQjHYskSgHNxUq4OLV4ort_0B8d8qdH4miNPGzvwtT8EN2GG46MMF_jAJ9av3NMGvrOTXuYA5meIWd5H8IkIqIXx9xRkofCqrDsivF4Wba0QnGy06meDEa_IcyTgDVEnOEF8qa1tU40ed9bLnTPfPmFxvE_O3ORnG-QKH1Uu84lsubKy2Rjvzlrv0K-v3LzH1-_qeb7OUsDp8OkpIyq0tIFRrl2zoGGTIV3JD7iIp7i7i4d774GfT0J92YoJv152og4CriTFqoowjYLrfPRaeUpFmQvVmABDcnu7jP8G1ZN_qRWVK_ozL0N9cagQVVMygoanDSmBIb22ZyCKvQTzMAzCUyypQbrJZVVoa6Sw-Hey8ejqKkAERlElpGNjUlSp5T1xmnNlU24gFCBhSZjqX02SLxLvZBeZZ77NNNMWZEMXKCVs2l6jayXVemuE2pANnOKDWCG4t5ZGYO20E5qmRnB3RZ50LpCbhp6dKzS8SGviZ2THGzPwzfaIvc60WnNCXKa0HbrT3kzLcxzhmT6DEBBfPpjycBrASKC9t3uMYx3fGGqdNUyNAErWEBx8m8yA1iVcpGBzGbtyp2hCULUPmfQ3-CQf-5BPtobhx83_l30DtkY7w7z508Ont0k5wBcNttV22R9MVu6WwDgFvp2GKg_AdP9RuY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Yes-associated+protein+1+and+transcriptional+coactivator+with+PDZ-binding+motif+activate+the+mammalian+target+of+rapamycin+complex+1+pathway+by+regulating+amino+acid+transporters+in+hepatocellular+carcinoma&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Park%2C+Yun-Yong&rft.au=Sohn%2C+Bo+Hwa&rft.au=Johnson%2C+Randy+L&rft.au=Kang%2C+Myoung-Hee&rft.date=2016-01-01&rft.eissn=1527-3350&rft.volume=63&rft.issue=1&rft.spage=159&rft_id=info:doi/10.1002%2Fhep.28223&rft_id=info%3Apmid%2F26389641&rft.externalDocID=26389641
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon